Filtered By:
Specialty: Drugs & Pharmacology
Condition: Multiple Sclerosis

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 158 results found since Jan 2013.

Subcutaneous Interferon- β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance
ConclusionSafety data from both clinical trial and post-marketing settings indicate that treatment with sc IFN- β1a does not increase stroke risk in patients with MS.FundingMerck KGaA, Darmstadt, Germany.
Source: Advances in Therapy - November 1, 2018 Category: Drugs & Pharmacology Source Type: research

Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Abstract The relevance of tyrosine kinase inhibitors (TKIs) in the treatment of malignancies has been already defined. Aberrant activation of tyrosine kinase signaling pathways has been causally linked not only to cancers but also to other non-oncological diseases. This review concentrates on the novel plausible usage of this group of drugs in neurological disorders, such as ischemic brain stroke, subarachnoid hemorrhage, Alzheimer's disease, multiple sclerosis. The drugs considered here are representatives of both receptor and non-receptor TKIs. Among them imatinib and masitinib have the broadest spectrum of ther...
Source: Current Neuropharmacology - November 26, 2015 Category: Drugs & Pharmacology Authors: Gagalo I, Rusiecka I, Kocic I Tags: Curr Neuropharmacol Source Type: research

FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)
The U.S. Food and Drug Administration (FDA) is warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) shortly after they received Lemtrada (alemtuzumab).
Source: FDA Center for Drug Evaluation and Research - What's New - November 29, 2018 Category: Drugs & Pharmacology Source Type: news

The role of IL-23/IL-17 axis in ischemic stroke from the perspective of gut-brain axis
Neuropharmacology. 2023 Mar 14:109505. doi: 10.1016/j.neuropharm.2023.109505. Online ahead of print.ABSTRACTBidirectional communication between central nervous system (CNS) and intestine is mediated by nerve, endocrine, immune and other pathways in gut-brain axis. Many diseases of CNS disturb the homeostasis of intestine and gut microbiota. Similarly, the dysbiosis of intestinal and gut microbiota also promotes the progression and deterioration of CNS diseases. IL-23/IL-17 axis is an important inflammatory axis which is widely involved in CNS diseases such as experimental autoimmune encephalomyelitis (EAE), multiple sclero...
Source: Neuropharmacology - March 16, 2023 Category: Drugs & Pharmacology Authors: Yang Jiang Yajie Dai Zhenquan Liu Yan Liao Shuyong Sun Xianghe Kong Jingjing Hu Yibo Tang Source Type: research

Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database
ConclusionsThe majority of implicated drugs belong to therapeutic groups that are already mentioned in different heat-illness prevention plans. But we also show that drugs aimed to treat multiple sclerosis and several cytokines were also associated with heat-related adverse effects.
Source: European Journal of Clinical Pharmacology - April 3, 2023 Category: Drugs & Pharmacology Source Type: research

Statins in neurological disorders: An overview and update
Publication date: October 2014 Source:Pharmacological Research, Volume 88 Author(s): Anna Maria Malfitano , Giuseppe Marasco , Maria Chiara Proto , Chiara Laezza , Patrizia Gazzerro , Maurizio Bifulco Statins have, at present, the potential to provide a new therapeutic target for various neurological diseases. It is well established that statins reduce cholesterol levels and prevent coronary heart disease. Moreover, evidence suggest that statins have additional properties such as endothelial protection via action on the nitric oxide synthase system as well as antioxidant, anti-inflammatory and anti-platelet effects. Thes...
Source: Pharmacological Research - November 6, 2014 Category: Drugs & Pharmacology Source Type: research

Fumaric acid esters promote neuronal survival upon ischemic stress through activation of the Nrf2 but not HIF-1 signaling pathway.
Abstract Oxidative stress is a hallmark of ischemic stroke pathogenesis causing neuronal malfunction and cell death. Up-regulation of anti-oxidative genes through activation of the NF-E2-related transcription factor 2 (Nrf2) is one of the key mechanisms in cellular defense against oxidative stress. Fumaric acid esters (FAEs) represent a class of anti-oxidative and anti-inflammatory molecules that are already in clinical use for multiple sclerosis therapy. Purpose of this study was to investigate whether FAEs promote neuronal survival upon ischemia, and analyze putative underlying molecular mechanisms in neurons. M...
Source: Neuropharmacology - January 19, 2016 Category: Drugs & Pharmacology Authors: Lin-Holderer J, Li L, Gruneberg D, Marti HH, Kuznets R Tags: Neuropharmacology Source Type: research

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation
Abstract Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are ubiquitously expressed. S1P-S1PR signaling has been well characterized in immune trafficking and activation in innate and adaptive immune systems. However, the full extent of its involvement in the pathogenesis of autoimmune diseases is not well understood. FTY720 (fingolimod), a non-selective S1PR modulator, significantly decreased annualized relapse rates in relapsing-remitting multiple sclerosis (MS). FTY720, which primarily targets S1P receptor 1 as a functional antagonist, arrests lymphocyte egress from secondary lymphoid tissues and reduce...
Source: Drugs - June 17, 2016 Category: Drugs & Pharmacology Source Type: research

Vitamin d intake and its protective role in multiple sclerosis: the checkmate to survivin?
Vitamin D has long been speculated to reduce the risk of multiple sclerosis (MS). However, its role in development and modulating the course of MS has yet to be clarified. To date, there is no scientific evidence for the use of vitamin D as monotherapy for MS in clinical practice and perplexities still exist on potential disadvantages of Vitamin D intake. We hypothesize that vitamin D may be effective against MS inhibiting survivin gene expression and thereby affecting the development and progression of the disease. However, decreased levels of survivin may lead to worse outcomes during the acute phase of cardiovascular co...
Source: Iranian Journal of Pharmaceutical Research - May 31, 2016 Category: Drugs & Pharmacology Source Type: research

Pharmacological targeting of the PDGF-CC signaling pathway for blood –brain barrier restoration in neurological disorders
Publication date: Available online 12 August 2016 Source:Pharmacology & Therapeutics Author(s): Sebastian A. Lewandowski, Linda Fredriksson, Daniel A. Lawrence, Ulf Eriksson Neurological disorders account for a majority of non-malignant disability in humans and are often associated with dysfunction of the blood–brain barrier (BBB). Recent evidence shows that despite apparent variation in the origin of neural damage, the central nervous system has a common injury response mechanism involving platelet-derived growth factor (PDGF)-CC activation in the neurovascular unit and subsequent dysfunction of BBB integrity. ...
Source: Pharmacology and Therapeutics - August 11, 2016 Category: Drugs & Pharmacology Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

The future of transcranial magnetic stimulation in neuroscience and neurology in the Middle East.
CONCLUSIONS: By paying special consideration to a Middle Eastern context, we aimed at illustrating the possibilities that TMS could bring for clinicians and patients in this nationally prioritized research field. PMID: 31173309 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 9, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research